Treatment of refractory gout remains a challenge on drug development. While pegloticase, a recombinant mammalian uricase modified with monomethoxyl poly(ethylene glycol) (mPEG) is effective in treating refractory gout, after continued treatment for 3 months biweekly at a therapeutic dose of 0.14 mg/kg body weight, it elicits an immune response against mPEG in nearly 20% of patients. For continued treatment of refractory gout, PEGylated uricases at monthly therapeutic doses below 4 mg/kg body weight have promise. To formulate uricases to achieve monthly therapeutic regimens requires pharmacodynamics simulation and experimentation including molecular engineering of uricases based on rational design and evolution biotechnology in combination to improve their inherent catalytic efficiency, thermostability and selectivity for urate over xanthine and optimization of the number and distribution of accessible reactive amino acid residues in native uricases for site-specific PEGylation with poly(ethylene glycol) derivatives with lower of immunogenicity than mPEG to retain activity, minimize immunogenicity and enhance the pharmacokinetics of the PEGylated uricase. These issues are briefly reviewed as a means to stimulate the development of safer uricase formulations for continued treatment of refractory gout. Drug Dev Res 73: 66-72, 2012. 
INTRODUCTION
In humans, xanthine is oxidized by xanthine oxidase (XO) into urate as the end product of purine catabolism [Ramazzina et al., 2006; Richette and Bardin, 2006] . Urate is mainly excreted through the kidney and partially through the gastrointestinal tract but is reabsorbed in kidney (Fig. 1) . Pathophysiological processes that accelerate purine catabolism and/or reduce kidney excretion of urate will elevate plasma urate levels. Hyperuricemia occurs when plasma urate levels are over the solubility of urate. The latter is usually associated with hyperxanthinemia, that is, plasma xanthine levels over the average in healthy individuals that can lead to the precipitation of xanthine resulting in kidney dysfunction [Band et al., 1970; Mughal et al., 2010] . Hyperuricemia is associated with urate precipitation with the formation of crystals that are involved in gout, tumor lysis syndrome (TLS), chronic kidney disease (CKD), and various cardiovascular diseases [Davidson et al., 2004; Kang and Nakagawa, 2005; Feig et al., 2008; Edwards, 2008; Feig, 2009; Richette and Bardin, 2010] .
Therapy for hyperuricemia-associated diseases is treated by agents that keep plasma urate concentrations from precipitating with the additional benefit of removing existing urate crystals. TLS is characterized by the acute onset of hyperuricemia during cancer chemotherapy [Davidson et al., 2004; Edwards, 2009; Mughal et al., 2010] . Gout, with a prevalence of about 1%, is characterized by the sustained elevation of plasma urate levels [Davidson et al., 2004; Kang and Nakagawa, 2005; Chohan and Becker, 2009; Richette and Bardin, 2010] . CKD is usually associated with hyperuricemia and has a prevalence of about 5% [Kang and Nakagawa, 2005; Sestigiani et al., 2008; Feig, 2009] .
Currently, available anti-hyperuricemia drugs act on XO, the urate transporter or urate itself. Allopurinol and febuxostat are anti-hyperuricemia drugs that competitively inhibit XO (Fig. 1) . Allopurinol is the first-line drug for treating gout and TLS, but refractory gout occurs when patients suffer from hypersensitivity or nonresponsiveness to allopurinol, intolerance to allopurinol toxicity, or drug-drug interactions with allopurinol [Vogt, 2005; >; Bardin, 2006, 2010; Fels and Sundy, 2008; Chohan and Becker, 2009; Edwards, 2009; Keenan and Pillinger, 2009; Mughal et al., 2010Terkeltaub, 2010 . Febuxostat is tolerated by most patients [Chohan and Becker, 2009; Keenan and Pillinger, 2009; Terkeltaub, 2010] , but its efficacy in treating refractory gout has not been proven. Probenecid is anti-hyperuricemia drug acting on the renal urate transporter ( Fig. 1) [Chohan and Becker, 2009; Richette and Bardin, 2010] but it is not widely used due to associated kidney and liver toxicity. Uricase is a unique antihyperuricemia drug acting on urate [Bessmertny et al., 2005; Vogt, 2005; Bardin, 2006, 2010; Fels and Sundy, 2008; Sestigiani et al., 2008; Sherman et al., 2008; Chohan and Becker, 2009; Mughal et al., 2010 ; Terkeltaub, 2010; Schlesinger et al., 2011] , catalyzing the oxidation of urate into hydrogen peroxide and 5-hydroxyisourate (HIU) [Ramazzina et al., 2006] . HIU spontaneously decomposes to allantoin and carbon dioxide. Allantoin is highly soluble in plasma with few pathological actions and is easily excreted through kidney.
Uricases are effective in diverse forms of hyperuricemia including refractory gout removing preexisting urate crystals in joints [Vogt, 2005; Richette and Bardin, 2006; Edwards, 2008; Fels and Sundy, 2008; Chohan and Becker, 2009; Schlesinger et al., 2011] and have negligible drug-drug interactions. Only uricases are effective in refractory gout, but available uricase formulations are unsuitable for continuous treatment.
PROBLEM OF URICASES TO TREAT REFRACTORY GOUT AND POTENTIAL SOLUTIONS
Any protein drug should have potent activity, negligible immunogenicity, and a long circulation half-life in vivo. The modification of exogenous proteins with monomethoxyl poly(ethylene glycol) (mPEG), that is, PEGylation, is a routine formulation approach for exogenous proteins to reduce their immunogenicity and improve their pharmacokinetics [Haag and Kratz, 2006; Gaberc-Porekar et al., 2008] . PEGylation routinely decreases protein activity, while mPEG is weakly immunogenic. Eukaryote and prokaryote uricases have low catalytic capacity with lower apparent activities at physiological pH and are sensitive to xanthine inhibition. Eukaryote uricases usually have lower thermostability, lower solubility, and a higher sensitivity to xanthine [Fridovich, 1965; Liao et al., 2005; Liu et al., 2009] . Hence, natural uricases themselves are unsatisfactory as therapeutic formations for treating refractory gout.
Raburicase and pegloticase are approved uricase formulations for treating hyperuricemia. Raburicase is a recombinant fungal uricase without structural modification and is used for short-term treatment of TLS [Bessmertny et al., 2005; Vogt, 2005; Richette and Bardin, 2006; Sestigiani et al., 2008] . Pegloticase is a chimera of porcine and baboon liver uricases and is designed for the continuous treatment of refractory gout [Sundy et al., 2007; Fels and Sundy, 2008; Sherman et al., 2008; Yue et al., 2008; Chohan and Becker, 2009; Terkeltaub, 2010; Schlesinger et al., 2011] . Following the initial intravenous infusion, pegloticase has a circulation half-life of 3-7 days. However, after six administrations at the required biweekly therapeutic dose of approximately 8 mg, an immune response develops against the mPEG moiety of pegloticase in nearly 20% patients [Sundy et al., 2007; Yue et al., 2008] . Repeated administration of other PEGylated drugs also result in detectable antibodies specifically against mPEG moiety with few antibodies being developed against the drug itself, causing an accelerated clearance [Tsuji et al., 1985; Cheng et al., 2000; Ganson et al., 2006; Ishida et al., 2006; Ishida and Kiwada, 2008; Sundy et al., 2007; Yue et al., 2008] . Despite the weak immunogenicity of mPEG, some PEGylated proteins can be used to treat chronic diseases for years [Pasut et al., 2008; Gaspar et al., 2009; Rodriguez-Torres et al., 2009; Foster, 2010] . For example, adenosine deaminase modified with mPEG can be safely used for nearly 10 years in patients with severe compliant immunodeficiency at weekly doses of about 20 mg/kg body weight [Gaspar et al., 2009] . PEGylated human interferon-a is successfully used to treat chronic hepatitis C at weekly therapeutic dose of about 4 mg/kg body weight for up to a year [RodriguezTorres et al., 2009; Foster, 2010] , while PEGylated asparginase from Escherichia coli can be used to treat leukemia patients at weekly therapeutic dose of about 30 mg/kg body weight for up to 2 years [Pasut et al., 2008] . Finally, monthly i.v. infusion of 10 mg raburicase, which can elicit an immune response in healthy individuals, was safely used for 3 years to treat a patient cotreated with immunosuppressors after kidney transplantation [Vogt, 2005] .
In light of these data, a PEGylated uricase has promise for safe, continuous treatment of refractory gout, and even CKD when patients have low immunoresponse capacity; the uricase is PEGylated with new PEG derivatives of lower immunogenicity and its therapeutic dose is too low to elicit an immune response. In practice, it is rare to find a patient with refractory gout with a low immunoresponse capacity a problem that is exacerbated by coadministration of immunosuppressors.
There have been few advances in the design of new PEG derivatives with lower immunogenicity than mPEG with PEG backbones having low immunogenicity [Su et al., 2010] . Without novel hydrophilic polymers of lower immunogenicity to formulate proteins, any PEGylated uricase for continued use in the treatment of refractory gout must have a therapeutic dose low enough to avoid eliciting an immunoresponse after repeated administrations.
In light of the safe continued administrations of a single-site PEGylated human interferon-a-a for several years, a PEGylated uricase at a monthly therapeutic dose below 4 mg/kg body weight may have promise for continued treatment of refractory gout. In clinical practice, the recommended biweekly i.v. dose of pegloticase is approximately 0.14 mg/kg body weight [Sundy et al., 2007; Yue et al., 2008; Schlesinger et al., 2011] . This dose is nearly 70 times of the threshold of the safe monthly dose with more PEG chains in PEGylated uricase than in a PEGylated interferon-a-a molecule. Continued administration of pegloticase will inevitably elicit a host immunoresponse via the mPEG moiety.
PEGylated proteins typically exhibit improved thermostability with higher solubility but lower activity than the native protein. A PEGylated uricase for chronic treatment of refractory gout under physiological conditions should have high catalytic capacity, a long thermo-inactivation half-life and high residual activity after PEGylation and should have a small quantity of PEG chains to mask its immunogenic sites. Therefore, molecular engineering should begin with a uricase of high activity and/or superior thermostability to produce uricase mutants with optimized number and distribution of accessible amino acid residues reacting with common activated PEG derivatives for site-specific PEGylation to mask immunogenic sites; new PEG chains or other suitable polymers of low immunogenicity should be designed for site-specific modification of uricases. Therapeutic doses of PEGylated uricases can be preliminarily evaluated by pharmacodynamics (PD) simulation followed by experimentation. These strategies should be integrated for site-specific PEGylation of uricases.
MOLECULAR ENGINEERING AND SITE-SPECIFIC PEGYLATION OF URICASES

Molecular Engineering to Enhance Inherent Catalytic Efficiency of Enzymes
Molecular engineering can be initiated via rational design, evolutionary biotechnology, or a combination of the two. Due to the low thermostability of most eukaryotic uricases [Liu et al., 2009] , bacterial uricases with better thermostability can be used as a starting point [Zhao et al., 2006 [Zhao et al., , 2009 .
The first technique for molecular engineering of an enzyme is rational design based on the detailed understanding of three-dimensional structure, the catalytic mechanism, and structure activity and/or thermostability correlation of the enzyme [Pan et al., 2005 [Pan et al., , 2007 [Pan et al., , 2008 Gao et al., 2006 Gao et al., , 2009 Zheng et al., 2008; Chen et al., 2009; Kumarasiri et al., 2009; Yang et al., 2009; Lonsdale et al., 2010] . Recently, computational design approaches have been successfully employed with some enzymes to improve their catalytic activities and thermostability [Gao et al., 2009] . Knowledge of the putative reaction pathway and free energy profile of an enzyme reaction determined by computation can be used to rationally design essential amino acid residue(s) mutants of uricase to decrease the free energy barrier of the reaction and increase uricase catalytic efficiency [Pan et al., 2005 [Pan et al., , 2007 [Pan et al., , 2008 Gao et al., 2006; Chen et al., 2009; Kumarasiri et al., 2009; Yang et al., 2009; Lonsdale et al., 2010] . Comparative computational studies on the interactions of uricase with urate and xanthine can facilitate rational design of uricase mutants to improve selectivity for urate. To improve the thermostability of uricase, determination of its thermoinactivation pathway can be used to design thermostable mutants based [Gao et al., 2009] .
Another technique for molecular engineering of an enzyme is evolutionary biotechnology in vitro mimicking the natural evolution of the enzyme in vivo. This does not require a three-dimensional structure of the enzyme but usually suffers from higher cost and longer time in generating and screening mutant libraries [Petrounia and Arnold, 2000; Voigt et al., 2000; Chica et al., 2005; Labrou, 2010] . Using this technique, a library of uricase mutants from a suitable starting uricase can be constructed for screening. The mutant library is ideally focused on amino acid residues in the vicinity of the active site [Chica et al., 2005] . During the mutant screen, xanthine saturated in physiological buffer with thermo-inactivation at 37°C can accelerate the discovery of desirable mutants. Efficient, validated screening methods for uricase mutants are currently unavailable.
Site-Specific PEGylation of Uricase Using PEG Chains of Lower Immunogenicity
Once engineered uricases with desirable inherent properties are identified, their modification with mPEG or similar hydrophilic polymers of lower immunogenicity can be used to improve their pharmacokinetics [Haag and Kratz, 2006; Gaberc-Porekar et al., 2008] . In the present review, only site-specific PEGylation and the design of new PEG derivatives will be briefly discussed.
Site-specific PEGylation is always preferred for the formulation of proteins based on the following considerations [Sato, 2002; Marsac et al., 2006] : after optimization of the number and distribution of accessible reactive amino acid residues of uricases for PEGylation, small or even negligible decreases in uricase activity after PEGylation can be sought with the immunogenic sites effectively masked; using lower degrees of PEGylation, there will be fewer PEG chains in PEGylated uricases and hence lower immunoresponsivity; fewer modified isomers simplify the purification of PEGylated uricases and evaluation of their effectiveness. Immunogenic sites on uricases can be predicted using bioinformatics [Bryson et al., 2010] . Knowledge of uricase structure-activity relationships together with predicted immunogenic sites can facilitate the engineering of limited numbers of accessible reactive amino acid residues, while the PEG chain structure can be optimized for lower immunogenicity with lower degrees of PEGylation, masking all predicted immunogenic sites. Due to the weak immunogenicity of mPEG, design of new PEG chains or suitable new hydrophilic polymers of lower immunogenicity while mandatory is challenging. PEG is a linear polymer; after PEGylation, one end of a PEG chain is linked to accessible reactive amino acid residues and the other end remains free. Antibodies detected in animals after repeat administration of diverse PEGylated drugs are typically specific for the methoxyl group of mPEG [Tsuji et al., 1985; Cheng et al., 2000; Ganson et al., 2006; Ishida et al., 2006; Sundy et al., 2007; Ishida and Kiwada, 2008; Yue et al., 2008] . Thus, PEG chains with groups other than a methoxyl at the free end are preferred; however, few of such PEG derivatives are known.
THERAPEUTIC DOSES OF FORMULATED URICASES Properties Affecting Therapeutic Doses of Formulated Uricases and Their Evaluations
Maximal catalytic efficiency of a formulated uricase in vivo is crucial in determining the therapeutic dose. PEGylated uricases usually have lower activity than the native enzyme. Under optimum reaction conditions, it is feasible to continuously monitor uricase reaction curve for kinetic analysis of reaction process to estimate the maximal catalytic efficiency [Liao et al., 2001 [Liao et al., , 2005 . Due to the interference from HIU with the ultraviolet absorbance of urate, the quantification of hydrogen peroxide is an alternative [Kahn and Tipton, 1998 ], but current conventional methods are able to quantify hydrogen peroxide for measuring uricase activities.
The circulation half-life in vivo of a formulated uricase is also critical in determining the therapeutic dose [Sarkissian et al., 2008; Feng et al., 2010; Zhang et al., 2010] . PEGylation usually enhances the thermostability of formulated proteins, but the circulation halflife of any formulated enzyme in vivo is inevitably shorter than its thermo-inactivation half-life in vitro under the same temperature and pH due to complex interactions with biomolecules in vivo. Usually, a fully modified enzyme has the highest thermostability and the longest in vivo half-life. If there are large enough differences in the thermo-inactivation and/or circulation half-life of modified uricase isoforms, kinetic analysis of the decrease in the total activities of a mixture of modification isoforms of the uricase can be used to estimate the thermo-inactivation or circulation half-life of the fully modified uricase .
The sensitivity of common uricases to xanthine and the association of hyperxanthinemia with hyperuricemia necessitates consideration of xanthine inhibition on the actions of uricases in vivo [Fridovich, 1965; Band et al., 1970; Liao et al., 2005] . In the plasma of TLS patients, the peak concentration of xanthine can be over 0.8 mM [Hande et al., 1979] and the treatment of TLS patients with allopurinol results in kidney dysfunction due to hyperxanthinemia [Band et al., 1970] . Thus, uricases with affinities for urate higher than those for xanthine are desirable, but none are known [Fridovich, 1965; Liao et al., 2005] . At a saturated level of xanthine (~0.22 mM at 37°C), eukaryotic uricases have negligible advantages over prokaryotic uricases in the elimination of plasma urate . To screen uricase mutants of higher affinities for urate than those for xanthine, kinetic analysis of reaction curves to estimate the competitive inhibition constants of xanthine is desirable [Liao et al., 2005] .
Estimation of Therapeutic Doses of Formulated Uricases
PD simulation for drugs can be used to estimate therapeutic doses and optimized administration intervals [Danhof et al., 2007 [Danhof et al., , 2008 . When formulated uricases with different inherent properties are prepared, PD simulation of actions of each can be carried out to estimate the potential monthly therapeutic dose for practical efficiency and cost. For PD simulation, the properties of a formulated uricase that affect its therapeutic dose and the factors affecting urate levels in vivo including the production of urate by XO, the transportation of urate from tissue pools into plasma, the excretion of urate via kidney, and so forth should be taken into account. Such PD simulation techniques are still under development for enzymes.
After comparison of simulated monthly therapeutic doses of uricase formulations, the detailed experimental evaluation of their pharmacokinetics and PD are still required. However, the development of hyperuricemic animal models is also challenging. Hyperuricemic animals treated with uricase inhibitors are unsuitable as uricase inhibitors have no selectivity for mammalian uricases over a formulated uricase as a candidate therapeutic agent. Furthermore, uricasedeficient mice have a short lifespan, and suffer from severe urate nephropathy [Wu et al., 1994; Kelly et al., 2001] . Alternatively, chicken and duck can be used as models to estimate the therapeutic dose of a modified uricase mutant in vivo [Ramazzina et al., 2006] . In addition, PD simulation techniques can be verified with experimental data of pharmacokinetics and PD of formulated uricases.
CONCLUSION
Currently, available formulated uricases are unsuitable for the chronic treatment of refractory gout, although a formulated uricase at a monthly therapeutic dose of below 4 mg/kg body weight shows some promise to refractory gout. Molecular engineering to enhance the efficacy of mutant uricases together with sitespecific PEGylation can lead to improved forms of formulated uricase. These will require efficient screens and PD simulation to estimate monthly therapeutic dosing for chronic treatment of refractory gout.
